MXPA04002561A - Entidades sistematicas que limitan la apoptosis y el uso de las mismas en el tratamiento medico. - Google Patents

Entidades sistematicas que limitan la apoptosis y el uso de las mismas en el tratamiento medico.

Info

Publication number
MXPA04002561A
MXPA04002561A MXPA04002561A MXPA04002561A MXPA04002561A MX PA04002561 A MXPA04002561 A MX PA04002561A MX PA04002561 A MXPA04002561 A MX PA04002561A MX PA04002561 A MXPA04002561 A MX PA04002561A MX PA04002561 A MXPA04002561 A MX PA04002561A
Authority
MX
Mexico
Prior art keywords
disorders
apoptosis
medical treatment
synthetic entities
mimicking
Prior art date
Application number
MXPA04002561A
Other languages
English (en)
Inventor
Joan Lazarowych Natalie
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of MXPA04002561A publication Critical patent/MXPA04002561A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan cuerpos sinteticos que tienen estructura tridimensional, y estan dimensionados y formados para simular celulas apoptoticas y cuerpos apoptoticos y que comprenden entidades portadoras de grupos laterales de fosfo-aminoacidos, tales como granulos. Ellos pueden ser administrados a un paciente, para aliviar una variedad de padecimientos tales como padecimientos portados por las celulas T (padecimientos autoinmunologicos), padecimientos inflamatorios, padecimientos neurodegenerativos y padecimientos de disfuncion endotelial.
MXPA04002561A 2001-09-18 2002-09-13 Entidades sistematicas que limitan la apoptosis y el uso de las mismas en el tratamiento medico. MXPA04002561A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32323401P 2001-09-18 2001-09-18
PCT/CA2002/001398 WO2003024423A1 (en) 2001-09-18 2002-09-13 Apoptosis-mimicking synthetic entities and use thereof in medical treatment

Publications (1)

Publication Number Publication Date
MXPA04002561A true MXPA04002561A (es) 2004-07-30

Family

ID=23258280

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002561A MXPA04002561A (es) 2001-09-18 2002-09-13 Entidades sistematicas que limitan la apoptosis y el uso de las mismas en el tratamiento medico.

Country Status (8)

Country Link
US (1) US20040265927A1 (es)
EP (1) EP1429727A1 (es)
JP (1) JP2005502725A (es)
AU (1) AU2002325740B2 (es)
CA (1) CA2458720A1 (es)
MX (1) MXPA04002561A (es)
NZ (1) NZ531508A (es)
WO (1) WO2003024423A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110361476A (zh) * 2019-08-09 2019-10-22 河南城建学院 一种山药酵素液的制备及其中游离氨基酸的检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT40447A (en) * 1984-03-29 1986-12-28 Sandoz Ag Process for preparing substituted alpha-amino acids and pharmaceutical compositions containing such compounds
DE58904595D1 (de) * 1988-04-19 1993-07-15 Hafslund Nycomed Pharma Neue alkylphosphonoserine, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel.
US6627396B1 (en) * 1999-10-28 2003-09-30 The Regents Of The University Of California Influenza sensor
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2319928A1 (en) * 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients

Also Published As

Publication number Publication date
WO2003024423A1 (en) 2003-03-27
JP2005502725A (ja) 2005-01-27
US20040265927A1 (en) 2004-12-30
AU2002325740B2 (en) 2007-07-26
NZ531508A (en) 2005-08-26
CA2458720A1 (en) 2003-03-27
EP1429727A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2006078782A3 (en) Compositions containing agm cells and methods of use thereof
HK1068885A1 (en) N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases n--
CR7921A (es) Formulaciones farmaceuticas liquidas de palonosetron
HK1091813A1 (en) 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
IL176721A0 (en) HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS
EP2669269A3 (en) Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
IL201977A (en) 6- (Pyrrolidine-3-Yl) -Pyrazolo [4,3- d] Pyrimidine-4-Ones, Pharmaceuticals Including Them and Their Use in the Preparation of Medicines to Treat Diseases
IL173369A (en) Combined pharmaceutical preparation containing g - csf and p1gf effective in stimulating mobilization of peripheral blood progenitor cells
WO2001085196A3 (en) Cxcr4 antagonist treatment of hematopoietic cells
IL169647A (en) Pyrimidines that inhibit HIV replication, use them to make pharmaceutical preparations and preparations containing them
ZA200609974B (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP2156843A3 (de) Verwendung von niedrig dosiertem Erythropoietin zur Behandlung von akuter oder chronischer Niereninsuffizienz und zur Behandlung von Wunden
IL179075A (en) Use of random copolymer preparations in the preparation of drugs for the treatment of diseases, the reduction of undesirable immune reactions and the treatment of multiple sclerosis and pharmaceutical preparations containing random copolymer preparations
IL148401A0 (en) Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
EP2060255A3 (en) Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
JP2005530735A5 (es)
EP1554306A4 (en) CONJUGATES COMPRISING A POLYMER AND PEPTIDES DERIVED FROM HIV GP41 AND THEIR USE IN THERAPY
MXPA04002561A (es) Entidades sistematicas que limitan la apoptosis y el uso de las mismas en el tratamiento medico.
EP1776126A4 (en) METHOD FOR THE USE OF REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS
WO2003068157A3 (en) Kinase inhibitors and methods of use thereof
HK1088926A1 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical proparations
EP2116616A3 (en) Genes differentially expressed in activated T cells and uses thereof
ATE254595T1 (de) 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten
EP1583545A4 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF PEPTIDES OF HIV GP41 AND ITS THERAPEUTIC USE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal